4568.T · Intrinsic value
Is Daiichi Sankyo Company, Limited (4568.T) overvalued or undervalued?
Daiichi Sankyo Company, Limited (4568.T) trades at the delayed market price of ¥2,759.50 a share. That price already implies revenue growth of 15.0% a year for 5 years. TickerWorth's fair value is ¥2,831.00 a share (priced within our range of ¥2,541.67 – ¥3,236.06). We do not call it over- or undervalued from inside our range.
Model by Miraaj Patel · generated from market data · Updated Oct 19, 2026 · How these pages are made
Is 4568.T fairly valued?
- Fair value
- ¥2,831.00
- Market price
- ¥2,759.50
- Upside to fair value
- +2.6%
- Verdict
- Priced within our range of ¥2,541.67 – ¥3,236.06
Reverse DCF: Today's price implies revenue growth of 15.0% a year for 5 years; our model assumes 12.4% a year on average over the same horizon.
What is 4568.T's TickerWorth Score?
Middle of the pack — real strengths and real weaknesses
Compared with Healthcare companies in Japan
Its strongest point: strong balance sheet. Its weakest: recent price trend has been weak.
- Value · 54 of 100
Cheaper than 54% of Healthcare companies worldwide
- Price vs worth · 52 of 100
- Quality · 61 of 100
More profitable than 61% of Healthcare companies worldwide
- Financial health · 68 of 100
Financially stronger than 68% of Healthcare companies worldwide
- Growth · 37 of 100
Growing faster than 37% of Healthcare companies worldwide
- Momentum · 10 of 100
Outperformed 10% of Healthcare companies worldwide over the past year
Confidence: High confidence · Scored
Get the Undervalued Company of the Week.
4568.T DCF valuation, input by input
TickerWorth's fair value for Daiichi Sankyo Company, Limited (4568.T) is ¥2,831.00 a share, against the delayed market price of ¥2,759.50 (priced within our range of ¥2,541.67 – ¥3,236.06). We do not call it over- or undervalued from inside our range. It is a model estimate, and every input behind it is sourced below. This is an educational model, not a price target or a recommendation.
Read the full reasoning
One of the lenses behind that blended figure is a discounted-cash-flow model, which on its own values 4568.T at about ¥2,542 per share. The rest of this page walks through that DCF — its assumptions, reverse-DCF and discount-rate sensitivity — because it is the auditable anchor of the blend.
The valuation discounts Daiichi Sankyo Company, Limited's projected free cash flows at a weighted-average cost of capital (WACC) of 9.9%, with a long-run terminal growth rate of 2.5%. About 73% of the enterprise value comes from the terminal value — the portion beyond the explicit forecast window — which is typical for a stable, cash-generative business and a reminder that small changes in the discount rate or terminal growth assumption swing the intrinsic value meaningfully.
Running the DCF in reverse — solving for the growth the current price already assumes — the market is implying roughly 15.0% annual revenue growth for 4568.T. Our base case instead compounds to about 12.4% a year over the same forecast, so the market is pricing in materially faster growth than our base case. The reverse-DCF is a quick sanity check: it reframes 'is this stock cheap?' as 'do I believe the growth the price requires?' rather than arguing over a single point estimate of fair value.
Sensitivity matters more than any single number. Across a reasonable band of discount-rate assumptions, 4568.T's modeled DCF value ranges from about ¥1,960 to ¥3,712 per share. If that range still sits below today's price, the market is optimistic relative to the model across the whole band; if it brackets the price, the stock is roughly fairly valued on our assumptions. Use the interactive slider to see exactly where your own cost-of-capital view lands.
How to read this page: the DCF fair value is what Daiichi Sankyo Company, Limited would be worth if its cash flows grow as modeled and are discounted at the stated WACC. The assumptions table shows every input and its source; the reverse-DCF shows what the market believes; the sensitivity band shows how fragile the answer is. None of this is investment advice — it is a transparent, auditable framework for forming your own view of 4568.T's intrinsic value. Figures update as new filings and prices come in.
Every input behind 4568.T's DCF
| Input | Value |
|---|---|
| Base-year revenueLive feed — totalRevenue (TTM) | ¥2,223,187,950,000 |
| Base EBIT marginComputed — reported operating margin exceeded the EBITDA margin (impossible); held to 12.0% so D&A stays positive | 12.0% |
| Forecast revenue growthESTIMATEAssumption — TickerWorth's 5-year explicit forecast | 21% → 17% → 13% → 8% → 4% |
| Risk-free rateLive feed — US 10-year Treasury yield (^TNX) | 5.1% |
| BetaLive feed — yfinance, 5-year monthly beta vs the S&P 500 (clamped to 0.4–2.5) | 1.10 |
| Terminal growthESTIMATEAssumption — TickerWorth house default 2.5%, held below WACC | 2.5% |
| Diluted sharesLive feed — sharesOutstanding | 1,820M |
| Market priceDelayed quote · as of 2026-10-19 17:02 UTC | ¥2,760 |
Change 4568.T's assumptions
The discount-rate dial and the editable model
ProChange growth, margin and WACC yourself — Pro (7-day free trial, card required).
What does Daiichi Sankyo Company, Limited do?
What does it do?
Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan and internationally. The company offers Enhertu for the treatment of HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule for colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3, as well as symptomatic TGCT; Vanflyta, a FLT3 inhibitor for the treatment of acute myeloid leukemia; Injectafer, a ferric carboxymaltose injection for the treatment of iron deficiency; and Datroway for the treatment of HR positive and HER2 negative breast cancer, as well as NSCLC. It operates in the Drug Manufacturers - General industry (Healthcare sector), headquartered in Japan. The company employs roughly 20,171 people.
How does it make money?
The business turns 2.2T in annual revenue into profit. Out of every $100 of sales, about $15 is left as operating profit (operating margin of 14.8%), after a 68% gross margin on the products/services it sells. After all costs, taxes and interest, 10.9% of revenue becomes bottom-line net profit.
Is it financially healthy?
Financially it looks solid: carries modest debt (0.3× equity), comfortably covers its short-term bills (2.9× current ratio), and is currently profitable.
4568.T insider trading
Insider filings are available for US-listed companies only.
Common questions
What is 4568.T's intrinsic value?
TickerWorth's blended fair value for Daiichi Sankyo Company, Limited (4568.T) is ¥2,831.00 per share, versus a market price of ¥2,759.50 (priced within our range of ¥2,541.67 – ¥3,236.06).
Is 4568.T overvalued or undervalued?
Priced within our range of ¥2,541.67 – ¥3,236.06 at ¥2,759.50. We don't call 4568.T overvalued or undervalued from a range. This is an educational estimate, not advice.
What discount rate is used for 4568.T?
A WACC of 9.9% and a terminal growth rate of 2.5%.
Is Daiichi Sankyo stock undervalued?
TickerWorth's fair value for Daiichi Sankyo Company, Limited (4568.T) is ¥2,831.00 against a market price of ¥2,759.50. Our read: Priced within our range of ¥2,541.67 – ¥3,236.06. This is a model estimate, not investment advice.
Daiichi Sankyo (4568.T) DCF valuation and fair value
Our fair value for Daiichi Sankyo Company, Limited (4568.T) is ¥2,831.00, built on a 9.9% discount rate (WACC) and 2.5% terminal growth. It blends our discounted-cash-flow model with other valuation lenses. Every assumption is listed on this page with its source.
What growth is priced into Daiichi Sankyo stock?
Today's price implies revenue growth of 15.0% a year for 5 years; our model assumes 12.4% a year on average over the same horizon. This is a reverse DCF: it holds our cash-flow model's other inputs and solves for the revenue growth that makes the model equal today's price of ¥2,759.50. A model estimate, not investment advice.
Daiichi Sankyo (4568.T) insider trading
We have no recent SEC Form 4 insider filings on file for Daiichi Sankyo Company, Limited (4568.T). Form 4 covers US-listed companies only.
Not investment advice. TickerWorth Score is a model output.
Educational tool. Every output reflects the assumptions shown — not a prediction and not investment advice. TickerWorth is not a licensed investment adviser, and these figures are estimates from public filings and market data that can be wrong.